CGON (CG Oncology) Moat Score: 4/10 (As of Jul. 01, 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $70.89
! 5 Warning Signs
View Full Analysis

What is CG Oncology Moat Score?

CG Oncology CGON -0.23% 12 Moat Score is 4 as of Jul. 01, 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 1,400 Biotechnology companies, CG Oncology ranks better than 88.79% on this metric.

CG Oncology has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

CG Oncology has Narrow Moat: CG Oncology Inc has a discernible but modest moat due to its focus on innovative cancer therapies and potential intellectual property. However, the biotech sector's inherent risks and competition from larger pharmaceutical companies constrain its moat strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CG Oncology might have Narrow Moat - Discernible but modest moat.

CG Oncology  (NAS:CGON) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CG Oncology Moat Score Related Terms

CGON vs COGT, SRRK, LGND: Moat Score Comparison

For the Biotechnology subindustry, CG Oncology's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Moat Score distribution charts can be found below:

* The bar in red indicates where CG Oncology's Moat Score falls into.


CGON
12GF Score
CG Oncology Inc CGON
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
CG Oncology (CGON) has a Moat Score of 4 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CG Oncology ranks #157 out of 1400 companies in the Biotechnology industry, placing it in the top 11.2%.
Is CG Oncology's Moat Score too high?
CG Oncology's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. CG Oncology's value of 4 is 100% above this industry median. Based on the distribution chart, CG Oncology ranks #157 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Moat Score compare to COGT and SRRK?
According to the Biotechnology industry distribution chart, CG Oncology ranks #157 out of 1400 companies for Moat Score. This places CG Oncology in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. CG Oncology's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CG Oncology's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CG Oncology's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CG Oncology (CGON), the current Moat Score is 4 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$70.89
Price